VIRUS ONCOLITICO

• Main Authors: SONENBERG, NAHUM, BELL, JOHN, CAMERON, STOJDL, DAVID, FRANCIS, BROWN, EARL, GARNET, MARIUS, RICARDO, MARCELLUS, ATKINS, HAROLD, LAWRENCE
• Format: Patent
• Language: Spanish
• Published: 01.11.2006
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Uso de un virus para la fabricación de un medicamento para reducir la viabilidad de una célula tumoral, en el que el virus es una cepa atenuada del virus de la estomatitis vesicular y en el que la célula tumoral es una célula de cáncer hematopoyético, un melanoma, un sarcoma, un tumor neuroendocrino, un carcinoma de pulmón o un carcinoma de colon. The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR-/-, STAT1-/- or both PKR-/- and STAT-/-. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.